BaellJB, HollowayGA: New substructure filters for removal of pan assay interference compounds [PAINS] from screening libraries and for their exclusion in bioassays. J Med Chem, 2010; 53:2719–2740.
2.
BaellJB: Observations on Screening-Based Research and Some Concerning Trends in the Literature. Future Med Chem, 2010; 2:1529–1546.
3.
BaellJB, FerrinsL, FalkH, NikolakopoulosG: PAINS: Relevance to Tool Compound Discovery and Fragment-Based Screening. Aust J Chem, 2013; 66:1483–1494.
4.
BistaM, SmithsonD, PecakA, et al.: On the mechanism of action of SJ-172550 in inhibiting the interaction of MDM4 and p53. PLoS ONE, 2012; 7:e37518.
5.
ShrimpJH, SorumAW, GarlickJM, GuaschL, NicklausMC, MeierJL: Characterizing the Covalent Targets of a Small Molecule Inhibitor of the Lysine Acetyltransferase P300. ACS Med Chem Lett, 2016; 7:151–155.
6.
BaellJB: Feeling nature's PAINS: Natural products, natural product drugs, and pan assay interference compounds (PAINS). J Nat Prod, 2016; 79:616–628.
7.
PouliotM, JeanmartS: Pan assay interference compounds (PAINS) and other promiscuous compounds in antifungal research. J Med Chem, 2015; 59:497–503.
8.
PeñaI, Pilar ManzanoM, CantizaniJ, et al.: New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: An open resource. Sci Rep, 2015; 5:8771.
9.
SykesML, BaellJB, KaiserM, et al.: Identification of compounds with anti-proliferative activity against Trypanosoma brucei brucei strain 427 by a whole cell viability based HTS campaign. PLoS Negl Trop Dis, 2012; 6:e1896.
